TrialCancer2010

Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.

William N William et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.